Gastroenterology Clinics of North America, Journal Year: 2025, Volume and Issue: unknown
Published: Jan. 1, 2025
Language: Английский
Nature Reviews Gastroenterology & Hepatology, Journal Year: 2025, Volume and Issue: unknown
Published: Jan. 31, 2025
Language: Английский
Citations
7
Alimentary Pharmacology & Therapeutics, Journal Year: 2024, Volume and Issue: 60(9), P. 1215 - 1233
Published: Aug. 20, 2024
Summary Background Dietary management of patients with inflammatory bowel disease (IBD) involves more than defining a therapeutic diet. The profusion ‘expert advice’ is not necessarily built on evidence. Aims To provide evidence‐based guidance all clinically relevant aspects nutritional and dietary IBD. Methods A comprehensive review the published literature was made. Results Four pillars should be considered in patients. First, status optimised, since myopenia visceral obesity are associated poorer outcomes, which can improved attention to their correction. Accurate point‐of‐care measurement body composition advocated identify problems, guide interventions monitor outcomes. Second, exclusive enteral nutrition Crohn's Disease Exclusion Diet partial reducing intestinal inflammation have sufficient evidence advocated. Multiple other approaches, while promising, insufficient recommended. Third, approaches important symptomatic control many non‐inflammatory scenarios. Finally, following healthy diet fundamental general health advocated, but optimal strategy unclear. precarious IBD together risks inadequacy maladaptive eating behaviours restrictive diets dictate involvement expert dietitians assessment personalised delivery interventions. Conclusions require specific interventional strategies that chosen by Optimal requires skills specialised dietitian.
Language: Английский
Citations
10
Alimentary Pharmacology & Therapeutics, Journal Year: 2025, Volume and Issue: unknown
Published: Jan. 16, 2025
Exclusive enteral nutrition (EEN) is an established dietary therapy for Crohn's disease but its role in ulcerative colitis remains unclear. To investigate the efficacy of EEN adults with active and compare variations treatment protocols, safety, tolerability adherence. We conducted a systematic search MEDLINE, Embase, Cochrane CENTRAL, Emcare, CINAHL, Web Science trial registries articles published from inception until July 21, 2024. included all experimental observational studies that described use colitis. This review was registered on PROSPERO (CRD42022319584). Of 3273 screened, we 10 (334 adults). Overall, there no difference between comparator remission induction (median follow-up 14 days, risk ratio (RR) 1.15, 95% confidence interval (CI) 0.71-1.85; 2 studies). In acute severe colitis, corticosteroid failure (RR 0.76, CI 0.48-1.20; studies) or colectomy 0.88, 0.51-1.51, n = during index admission. The pooled discontinuation rate 3% (95% 0-10; 9 There heterogeneity design, methodology assessment outcomes. well tolerated low However, insufficient evidence to support as adjunctive standard care. Further, well-designed reproducible endpoints are necessary evaluate effectiveness. 2022 CRD42022319584.
Language: Английский
Citations
2
International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(7), P. 3071 - 3071
Published: March 27, 2025
Chronic inflammation is a pivotal driver in the progression of atherosclerosis, significantly contributing to burden cardiovascular disease (CVD). Patients with chronic inflammatory diseases, such as bowel diseases (IBDs) (e.g., ulcerative colitis and Crohn's disease), rheumatological disorders, well individuals auto-immune (such systemic lupus erythematosus), present higher risk major adverse cardiac events (MACEs). Despite their elevated CVD risk, these populations remain underrepresented research, leading critical underestimation (CVR) clinical practice. Furthermore, even recent CVR scores poorly predict specific populations. This narrative review examines physiopathological mechanisms linking inflammation, immunomodulation, thrombosis events. We data from epidemiological studies trials explore potential benefits anti-inflammatory immunomodulatory therapies. existing evidence, significant gaps knowledge remain. Future research mandatory, focusing on innovative strategies for stratification optimization, including lipidomics, proteomics, advanced markers, microbiota profiling, imaging. Addressing unmet needs will enhance understanding enabling tailored interventions better outcomes.
Language: Английский
Citations
2
Clinical Gastroenterology and Hepatology, Journal Year: 2024, Volume and Issue: 23(3), P. 419 - 427.e3
Published: July 25, 2024
Language: Английский
Citations
7
Nutrition Journal, Journal Year: 2025, Volume and Issue: 24(1)
Published: Jan. 23, 2025
Ulcerative colitis (UC) has experienced a steady increase in global incidence and prevalence recently. Current research into UC pathogenesis focuses on the complex interplay of genetic environmental factors with immune system gut microbiome, leading to disruption intestinal barrier. Normally, epithelium, interact maintain homeostasis. However, when this equilibrium is disturbed, harmful cycle dysbiosis, dysregulation, inflammation emerges, resulting barrier dysfunction progression. Among various risk factors, diet significantly influences epithelial integrity architectural stability through both direct indirect mechanisms, shaping entire continuum from pre-clinical prevention active phase treatment remission maintenance. This review provides insights impact dietary content eating behaviors UC, focusing specific food, food groups, nutrients, intermittent fasting, while providing detailed explanation why microbiota may mediate sustained effects across all stages UC. Additionally, it addresses limitations current studies, explores underexamined areas proposes potential directions for future expansion. Not applicable.
Language: Английский
Citations
1
European Journal of Clinical Investigation, Journal Year: 2025, Volume and Issue: unknown
Published: Jan. 24, 2025
Abstract Background The Crohn's disease exclusion diet (CDED) has been shown to induce remission in adult (CD) patients. aim of the study is provide additional evidence‐based validation. Methods We conducted an open‐label, randomized trial on CD patients with mild‐to‐moderate symptoms assess CDED efficacy inducing symptomatic using Mediterranean as control. evaluate demographic data, body mass index (BMI), Harvey‐Bradshaw Index (HBI), faecal calprotectin, and serum inflammatory indices at baseline, 12, 24 weeks. Bioelectrical impedance analysis (BIA) was used ensure safety group every 12 Results Twenty‐four were assigned CDED, 21 controls, no baseline differences among parameters considered. Five dropped out due intolerance within first 6 At weeks, showed significantly lower HBI higher rates than controls. By increased (70.8% vs. 38.1% weeks 79.2% 42.9% weeks; p = .027 < .0001, respectively), fibrinogen levels group. administration associated a significant decrease BMI (25.8 kg/m 2 –24.5 , .047), although BIA fat (18.2%–15.5%, .0001), while fat‐free cellular ( .001 .042, respectively) remained stable Conclusions effective appeared be safe well‐accepted.
Language: Английский
Citations
1
Nutrients, Journal Year: 2025, Volume and Issue: 17(4), P. 620 - 620
Published: Feb. 9, 2025
Nutriepigenetics, the study of nutritional effects on gene expression, offers new insights into clinical variability and relapse frequency inflammatory bowel disease (IBD). As older adult populations are frequently unrepresented in literature regarding their nutrition's influence we considered that studying this aspect would shed light population group. We conducted a prospective observational 60 IBD patients, categorized by age, residence, nutrition access. Patients were grouped according to age groups ("young"-old-65-74 years old old-old-75-86 old), gender, type, organic diet preference, Simple Clinical Colitis Activity Index (SCCAI), Harvey-Bradshaw (HBI) at diagnosis after change. All patients followed up Fundeni Institute Bucharest, Romania, received personalized dietary recommendations, accordance with European guidelines. Our findings revealed was predominantly had positive impact decreasing number episodes, irrespective type. Predominant diets, rich dairy saturated fats, mostly from non-organic sources, exacerbated inflammation increased frequencies relapses. Older who adopted reduction thus proving is an important part treatment regimen population.
Language: Английский
Citations
1
Food Bioscience, Journal Year: 2025, Volume and Issue: unknown, P. 106123 - 106123
Published: Feb. 1, 2025
Language: Английский
Citations
1
Nutrition Reviews, Journal Year: 2025, Volume and Issue: unknown
Published: Feb. 24, 2025
Abstract Context Supplementation with dietary components is a promising approach for the treatment of inflammatory bowel disease (IBD). Objective The aim was to examine effects supplements on experimental animal models IBD. Data Sources Articles were selected from 2016 2021 and specific databases (PubMed, Embase, Scopus). Extraction Forty-nine studies analyzed. Analysis Of 49 studies, 8 investigated supplementation oils/polyunsaturated fatty acids, 5 flavones, prebiotics probiotics, 6 amino 4 fruits, vegetables, 2 minerals, vitamins, 3 plants, polyphenols, various sources. Polyunsaturated prebiotics, probiotics are among most extensively studied compounds. Protection associated reducing inflammation oxidative stress, protecting epithelial barrier altering microbiota; however, more rigorous protocols needed definitively confirm their protective enable translational research. Fruits, plant compounds, other hand, should be further deserve attention in Conclusion results included here support research into beneficial Some advanced have presented elaborate protocols, while others still require an increase knowledge. identification that can improve course IBD could important lasting impact Systematic Review Registration PROSPERO registration no. CRD42022295260.
Language: Английский
Citations
1